The Scientific Advisory Board (SAB) for Susan G. Komen for the Cure® provides strategic guidance and direction for the Komen organization, in particular the research and scientific programs, and has played a key role in guiding and prioritizing Komen's global research investment. The SAB also serves as the executive committee of the Komen Scholars.
The SAB is led by the Chief Scientific Advisor and is comprised of leaders in breast cancer research, clinical practice and advocacy who have made significant contributions to advancing the field and are committed to furthering Komen's mission.
|
Eric P. Winer, M.D., is chief scientific advisor and chair of the Scientific Advisory Board and Komen Scholars for Susan G. Komen for the Cure. In addition to his responsibilities at Susan G. Komen for the Cure, Dr. Winer serves as Chief, Division of Women’s Cancers and the Thompson Senior Investigator in Breast Cancer Research at Dana-Farber Cancer Institute, where he leads a multidisciplinary group of clinicians and investigators focused on caring for individuals with breast cancer and identifying new and better approaches to treatment. He is also a Professor of Medicine at Harvard Medical School. Dr. Winer received his undergraduate and medical degrees from Yale University. After completing internal medicine and medical oncology training at Yale and Duke, he was on the faculty at Duke Medical Center for eight years before moving to Dana-Farber Cancer Institute in 1997. Dr. Winer is co-chair of the Alliance Breast Committee. Read more
|
|
Myles Brown, M.D., is Professor of Medicine at Harvard Medical School and Director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. His research focuses on understanding the role of steroid hormones receptors and their co-regulators in breast and prostate cancers. |
|
Powel Brown, M.D., Ph.D., is Professor and Chair of the Department of Clinical Cancer Prevention, John Charles Cain Distinguished Chair, and Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. His laboratory and clinical efforts are focused on developing novel strategies for the treatment and prevention of estrogen receptor-negative (ER-negative) breast cancer.
|
.bmp "Amelie G. Ramirez Bio Picture")
|
Amelie G. Ramirez, Dr.PH, an internationally recognized cancer and chronic disease health disparities researcher and spokesperson, is a professor of epidemiology and biostatistics at The University of Texas Health Science Center at San Antonio, where she also is founding director of the Institute for Health Promotion Research, which researches health disparities among minorities. |
|
George W. Sledge, M.D., is the Ballve-Lantero Professor of Oncology and Professor of Laboratory Medicine and Pathology at Indiana University School of Medicine, and co-director of the breast cancer program at the Indiana University Melvin and Bren Simon Cancer Center. A pioneer in the development of novel therapies for breast cancer, Dr. Sledge was awarded the Brinker Award for Scientific Distinction in 2006. |
 |
Chris Tannous, Ph.D., a two-time breast cancer survivor, is President and Public Policy Chair of the Orange County Affiliate of Susan G. Komen for the Cure, national delegate to the Global Initiative, member of the steering committee for the Komen Advocates in Science, and consumer reviewer of research grants for the Department of Defense’s Congressionally Directed Medical Research Program in breast cancer. |
